인쇄하기
취소

GSK Korea introduces PritorPlus, combination therapy of telmisartan plus HCTZ

Published: 2003-10-16 06:57:00
Updated: 2003-10-16 06:57:00
GlaxoSmithKline Korea launched PritorPlus, a combination medication of telmisartan and diruretic hydrochlrorothiazide, in the domestic market on October 6 after approval from the Korea Food and Drug Administration last month. After approval from the US FDA in October 2000, PritorPlus has been marketed in many countries including Europe.

The company officials explained that the therapeutic re...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.